BR112014025416A8 - Agentes antimaláricos, composição farmacêutica compreendendo-os e uso dos mesmos - Google Patents

Agentes antimaláricos, composição farmacêutica compreendendo-os e uso dos mesmos

Info

Publication number
BR112014025416A8
BR112014025416A8 BR112014025416A BR112014025416A BR112014025416A8 BR 112014025416 A8 BR112014025416 A8 BR 112014025416A8 BR 112014025416 A BR112014025416 A BR 112014025416A BR 112014025416 A BR112014025416 A BR 112014025416A BR 112014025416 A8 BR112014025416 A8 BR 112014025416A8
Authority
BR
Brazil
Prior art keywords
antimalaryal
agents
pharmaceutical composition
composition including
processes
Prior art date
Application number
BR112014025416A
Other languages
English (en)
Other versions
BR112014025416B1 (pt
BR112014025416A2 (pt
Inventor
Hugh Gilbert Ian
Norcross Neil
Baragana Ruibal Beatriz
Porzelle Achim
Original Assignee
Univ Dundee
Medicines For Malaria Venture Mmv
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee, Medicines For Malaria Venture Mmv, Merck Patent Gmbh filed Critical Univ Dundee
Publication of BR112014025416A2 publication Critical patent/BR112014025416A2/pt
Publication of BR112014025416A8 publication Critical patent/BR112014025416A8/pt
Publication of BR112014025416B1 publication Critical patent/BR112014025416B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO-OS E USO DOS MESMOS. A presente invenção refere-se a uma nova classe de inibidores quinolona-4-carboxamida do Pf3D7 da Fórmula geral (I) em que R1, R2, R3, R4, R5, R6, R7, R8 e X são como definidos neste pedido de patente, ao seu uso na medicina e no tratamento de malária, particularmente, a composições os contendo, a processos para prepará-los e a intermediários usados em tais processos.
BR112014025416A 2012-04-10 2013-03-14 agentes antimaláricos, composição farmacêutica compreendendo-os e uso dos mesmos BR112014025416B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1206280.8A GB201206280D0 (en) 2012-04-10 2012-04-10 Anti-malarial agents
PCT/GB2013/050633 WO2013153357A1 (en) 2012-04-10 2013-03-14 Anti-malarial agents

Publications (3)

Publication Number Publication Date
BR112014025416A2 BR112014025416A2 (pt) 2013-10-17
BR112014025416A8 true BR112014025416A8 (pt) 2018-06-12
BR112014025416B1 BR112014025416B1 (pt) 2020-04-22

Family

ID=46177063

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025416A BR112014025416B1 (pt) 2012-04-10 2013-03-14 agentes antimaláricos, composição farmacêutica compreendendo-os e uso dos mesmos

Country Status (16)

Country Link
US (1) US9115088B2 (pt)
EP (1) EP2836483B1 (pt)
JP (1) JP6088639B2 (pt)
CN (1) CN104302624B (pt)
BR (1) BR112014025416B1 (pt)
CA (1) CA2870140C (pt)
ES (1) ES2587683T3 (pt)
GB (1) GB201206280D0 (pt)
HU (1) HUE030572T2 (pt)
IN (1) IN2014DN09314A (pt)
MY (1) MY166153A (pt)
PH (1) PH12014502285B1 (pt)
PT (1) PT2836483T (pt)
SG (1) SG11201406548WA (pt)
WO (1) WO2013153357A1 (pt)
ZA (1) ZA201408094B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610724D0 (en) * 2016-06-20 2016-08-03 Univ Dundee Anti-infective agents
CN108101842B (zh) * 2017-12-29 2021-04-30 山东诚汇双达药业有限公司 一种2-羟基-4-羧基喹啉的制备方法
EP3773549A1 (en) 2018-04-11 2021-02-17 Merck Patent GmbH Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination
CN111084774B (zh) * 2019-11-29 2021-06-15 中国科学院广州生物医药与健康研究院 吡咯烷类化合物组合物在制备抗疟疾药物中的应用
WO2021149692A1 (en) * 2020-01-21 2021-07-29 Eisai R&D Management Co., Ltd. Novel antimalarial agent containing heterocyclic compound
EP3892332A1 (en) * 2020-04-09 2021-10-13 University Of Kentucky Research Foundation New anti-malarial agents
WO2024089045A1 (en) * 2022-10-24 2024-05-02 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Tasl mimicking molecules and applications thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2502264A (en) 1946-06-25 1950-03-28 Us Sec War Quinoline derivatives having antimalarial properties
JPH0873355A (ja) * 1994-09-02 1996-03-19 Mitsui Toatsu Chem Inc 抗マラリア薬耐性克服剤
TR199800854T2 (xx) * 1995-11-16 1998-08-21 F.Hoffmann-La Roche Ag Antis�tma kinolin t�revleri.
JP2002505689A (ja) * 1997-06-19 2002-02-19 セプレイコー インコーポレイテッド キノリン−インドール抗菌剤、それらに関する用途及び組成物
EP1940814B1 (en) * 2005-10-21 2013-05-22 Actelion Pharmaceuticals Ltd. Piperazine derivatives as antimalarial agents

Also Published As

Publication number Publication date
MY166153A (en) 2018-06-06
HUE030572T2 (en) 2017-05-29
CA2870140C (en) 2018-06-26
EP2836483A1 (en) 2015-02-18
ZA201408094B (en) 2017-08-30
GB201206280D0 (en) 2012-05-23
PH12014502285A1 (en) 2014-12-15
JP2015512930A (ja) 2015-04-30
BR112014025416B1 (pt) 2020-04-22
US9115088B2 (en) 2015-08-25
PH12014502285B1 (en) 2014-12-15
CN104302624A (zh) 2015-01-21
PT2836483T (pt) 2016-08-26
US20150045354A1 (en) 2015-02-12
IN2014DN09314A (pt) 2015-07-10
EP2836483B1 (en) 2016-07-27
WO2013153357A1 (en) 2013-10-17
CA2870140A1 (en) 2013-10-17
ES2587683T3 (es) 2016-10-26
BR112014025416A2 (pt) 2013-10-17
JP6088639B2 (ja) 2017-03-01
SG11201406548WA (en) 2015-01-29
CN104302624B (zh) 2016-01-13

Similar Documents

Publication Publication Date Title
CL2017002650A1 (es) Compuestos novedosos
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112014025416A8 (pt) Agentes antimaláricos, composição farmacêutica compreendendo-os e uso dos mesmos
BR112015005168A2 (pt) Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
PH12015500387A1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
PH12015501385A1 (en) Autotaxin inhibitors
UY33078A (es) Derivados de imidazoquinolina
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
ECSP14013215A (es) Compuestos novedosos
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
ECSP15013883A (es) Benzamidas
BR112014027669A2 (pt) aminas bicíclicas c-17 de triterpenoides com atividade inibidora de maturação de hiv
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
ECSP17069696A (es) Compuestos novedosos
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
CL2017002660A1 (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: UNIVERSITY OF DUNDEE (GB)

Free format text: A FIM DE ATENDER AS DUAS TRANSFERENCIAS, REQUERIDAS ATRAVES DA PETICAO NO 860160043736 DE 23/02/2016, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

Owner name: UNIVERSITY OF DUNDEE (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: MMV MEDICINES FOR MALARIA VENTURE (CH)

B25A Requested transfer of rights approved

Owner name: MERCK PATENT GMBH (DE)

B65X Notification of requirement for priority examination of patent application
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2013, OBSERVADAS AS CONDICOES LEGAIS.